Patents by Inventor Annick Goergler

Annick Goergler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirocyclic compounds
    Patent number: 12662488
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: June 23, 2026
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • Indazole derivatives
    Patent number: 12552801
    Abstract: The invention provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as described herein. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: February 17, 2026
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Annick Goergler, David Stephen Hewings, Georg Jaeschke, Christa Ulrike Obst-Sander, Antonio Ricci
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20260042782
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: October 20, 2025
    Publication date: February 12, 2026
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • Heterocyclic compounds for medical treatment
    Patent number: 12528797
    Abstract: The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: January 20, 2026
    Inventors: Christopher G. Nasveschuk, Roger Norcross, Fabian Dey, Annick Goergler, Eric Andre Kusznir
  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 12486290
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: May 12, 2025
    Date of Patent: December 2, 2025
    Assignee: C4 THERAPEUTICS, INC.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • EGFR inhibitors for the treatment of cancer
    Patent number: 12479849
    Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 25, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • EGFR INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20250289824
    Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.
    Type: Application
    Filed: May 28, 2025
    Publication date: September 18, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20250282780
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: February 13, 2025
    Publication date: September 11, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20250270234
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: May 12, 2025
    Publication date: August 28, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 12371442
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: May 8, 2023
    Date of Patent: July 29, 2025
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • Dihydrobenzimidazolones for medical treatment
    Patent number: 12365681
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: July 22, 2025
    Assignee: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • EGFR inhibitor for the treatment of cancer
    Patent number: 12344613
    Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: July 1, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • DIHYDROQUINOLINONES FOR MEDICAL TREATMENT
    Publication number: 20250084055
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: August 15, 2024
    Publication date: March 13, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Spirocyclic compounds
    Patent number: 12227504
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 18, 2025
    Assignee: C4 Therepeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers
    Patent number: 12209091
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 28, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Dihydroquinolinones for medical treatment
    Patent number: 12091397
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: September 17, 2024
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • GLUTARIMIDES FOR MEDICAL TREATMENT
    Publication number: 20240199638
    Abstract: The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: October 30, 2023
    Publication date: June 20, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
  • EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
    Publication number: 20240158418
    Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT
    Publication number: 20240109889
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 4, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20240076300
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 7, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher